GlassScriptPhysician profile
Michael J Nowicki
NPI 1649215526
$2,363.92
in general payments reported to CMS, 2019-2025
11 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $33.65 · 2021: $338 · 2022: $393 · 2023: $445 · 2024: $609 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,467.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $827.07 | 2021-2025 | Gattex, Eohilia |
| Abbvie INC. | $405.24 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $285.95 | 2024-2025 | Bylvay, Iqirvo |
| Mirum Pharmaceuticals, INC. | $214.86 | 2022-2024 | Livmarli |
| Albireo Pharma, INC. | $180.50 | 2022-2023 | Bylvay |
| Nestle Healthcare Nutrition INC. | $116.07 | 2021-2023 | |
| Qol Medical, LLC | $110.86 | 2022-2024 | Sucraid, Sucraid |
| Genzyme Corporation | $101.92 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $58.45 | 2024-2025 | Dupixent |
| Travere Therapeutics, INC. | $49.05 | 2020-2022 | |
| Applied Medical Technology INC | $13.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Nowicki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.